cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Tg Therapeutics Inc
23 own
22 watching
Current Price
$32.2
$1.25
(4.04%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
2,148.92M
52-Week High
52-Week High
36.84000
52-Week Low
52-Week Low
12.84000
Average Volume
Average Volume
2.79M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization2,148.92M
icon52-Week High36.84000
icon52-Week Low12.84000
iconAverage Volume2.79M
iconDividend Yield--
iconP/E Ratio--
What does the Tg Therapeutics Inc do?
TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program in the field of hematological malignancies; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. is headquartered in New York, New York.
Read More
How much money does Tg Therapeutics Inc make?
News & Events about Tg Therapeutics Inc.
PR Newswire
1 year ago
Thinking about buying stock in Eloxx Pharmaceuticals, Micron Technology, Emergent Biosolutions, Inflarx NV, or TG Therapeutics? Thinking about buying stock in Eloxx Pharmaceuticals, Micron Technology, Emergent Biosolutions, Inflarx NV, or TG Therapeutics? PR Newswire NEW YORK, April 10, 2023 NEW...
Benzinga
1 year ago
Latest Ratings for TGTX DateFirmActionFromTo Jan 2022HC Wainwright & Co.MaintainsBuy Jan 2022HC Wainwright & Co.MaintainsBuy Dec 2021Evercore ISI GroupMaintainsOutperform View More Analyst Ratings for TGTX View the Latest Analyst Ratings read more...
Globe Newswire
1 year ago
NEW YORK, March 31, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc.(NASDAQ: TGTX),today announced that the Committee for Medicinal Productsfor Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of BRIUMVI (ublituximab-xiiy) for the ...
Ticker Report
1 year ago
TG Therapeutics, Inc. (NASDAQ:TGTX Get Rating) Equities research analysts at Cantor Fitzgerald reduced their FY2023 EPS estimates for TG Therapeutics in a research note issued to investors on Wednesday, March 1st. Cantor Fitzgerald analyst P. Agrawal now anticipates that the ...
Globe Newswire
1 year ago
NEW YORK, March 03, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc.(NASDAQ: TGTX),today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the ...
Frequently Asked Questions
Frequently Asked Questions
What is Tg Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Tg Therapeutics Inc shares?
plus_minus_icon
How can I buy Tg Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Tg Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Tg Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Tg Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Tg Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Tg Therapeutics Inc?
plus_minus_icon
What percentage is Tg Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Tg Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$32.2
$1.25
(4.04%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
$90.73
$0.99 (1.10 %)
Viking Therapeutics, Inc.
Viking Therapeutics, Inc.
$42.25
$0.76 (1.83 %)
PROQR THERAPEUTICS NV
PROQR THERAPEUTICS NV
$2.63
$0.04 (1.54 %)
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$3.21
$0.00 (0.00 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
$90.73
$0.99 (1.10 %)
Viking Therapeutics, Inc.
Viking Therapeutics, Inc.
$42.25
$0.76 (1.83 %)
PROQR THERAPEUTICS NV
PROQR THERAPEUTICS NV
$2.63
$0.04 (1.54 %)
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$3.21
$0.00 (0.00 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00